Start of a rally, page-55

Optiscan will have learned its lessons from the Pentax deal, when it was screwed with insufficient royalties! Additionally we have an experienced accountant on “board” now, who knows how profits should look like!                           Orders for the Zeiss “ConVivo” will roll in strongly as no hospital in the world with a good reputation can afford to loose patients only because cancerous cells around brain tumor margins were overlooked because a ConVivo was not available! Additionally there is a strong market existing for Oil’s own brand Five2, Viewnvivo, which will be able to be of enormous use in so many scientific fields around the world as you can see listed in Optiscan’s website! In five days we will know more again!